Search Results - "Turba, Elyce"

Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia by Chavez, Julio C., MD, Piris-Villaespesa, Miguel, MD, Dalia, Samir, MD, Powers, John, PhD, Turba, Elyce, RN, Nodzon, Lisa, ARNP, Komrokji, Rami, MD, Sokol, Lubomir, PhD, Locke, Frederick L., MD, Lancet, Jeffrey, MD, Sotomayor, Eduardo M., MD, Kharfan-Dabaja, Mohamed A., MD, Pinilla-Ibarz, Javier, MD, PhD

“…Highlights • Chronic lymphocytic leukemia (CLL) remains an incurable disease with conventional chemotherapy or chemoimmunotherapy. • Lenalidomide and rituximab…”
Get full text

A Single-Arm, Open-Label Phase 2 Pilot Study of Vyxeos (CPX-351) in Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia by Shah, Bijal D., Rozario, Nicole, Turba, Elyce P., Bello, Celeste, Chavez, Julio C., Sokol, Lubomir, Brayer, Jason, Lancet, Jeffrey E.

“…Introduction: Vyxeos® is a liposomal formulation employing a 1:5 molar ratio of daunorubicin:cytarabine. Clinical trials in high risk acute myeloid leukemias…”
Get full text

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis by Komrokji, Rami S., Seymour, John F., Roberts, Andrew W., Wadleigh, Martha, To, L. Bik, Scherber, Robyn, Turba, Elyce, Dorr, Andrew, Zhu, Joy, Wang, Lixia, Granston, Tanya, Campbell, Mary S., Mesa, Ruben A.

“…Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1. It demonstrated a favorable…”
Get full text

Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol by Skelton, William Paul, Turba, Elyce, Sokol, Lubomir

Get full text

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function by Chavez, Julio C., Grajales-Cruz, Ariel F, Volpe, Virginia Olivia, Turba, Elyce P., Nodzon, Lisa, Sahakian, Eva, Rozario, Nicole, Pinilla Ibarz, Javier

“…Background: Chronic lymphocytic leukemia (CLL) is the most common chronic leukemia. Patients in active surveillance with untreated high-risk CLL (defined as…”
Get full text

Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Retrospective, Single-Institution Analysis Based on Risk Features and Debulking Strategy with Anti-CD20 Monoclonal Antibody by Grajales-Cruz, Ariel F, Chavez, Julio, Volpe, Virginia Olivia, Sandoval-Sus, Jose, Shah, Bijal, Bello, Celeste, Sokol, Lubomir, Fisher, Shanel, Nair, Rajesh R, Seongseok, Yun, Saeed, Hayder, Isenalumhe, Leidy, Turba, Elyce P., Nodzon, Lisa, Pinilla Ibarz, Javier

“…Background: The treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) has continued to evolve in recent years, offering the patients…”
Get full text

Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis by Chavez, Julio C, Grajales, Ariel, Sandoval-Sus, Jose, Turba, Elyce, Nodzon, Lisa, Uriepero-Palma, Angimar, Ammad-Ud-Din, Mohammad, Sahakian, Eva, Komrokji, Rami, Sokol, Lubomir, Locke, Frederick L, Shah, Bijal, Lancet, Jeffrey, Sotomayor, Eduardo M, Kharfan-Dabaja, Mohamed A., Bello, Celeste, Pinilla-Ibarz, Javier

“…Advancements in frontline therapy and chemotherapy-sparing treatments in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have altered the…”
Get full text

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naïve Chronic Lymphocytic Leukemia by Grajales-Cruz, Ariel Felipe, Chavez, Julio C., Turba, Elyce P., Nodzon, Lisa, Perez Leal, Francisco, Sandoval-Sus, Jose, Komrokji, Rami S., Locke, Frederick L., Kharfan-Dabaja, Mohamed A, Shah, Bijal D., Sokol, Lubomir, Bello, Celeste M., Pinilla Ibarz, Javier

“…Background: New targeted therapies continue to show improved efficacy in various stages of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL),…”
Get full text

Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma by Abramson, Jeremy S., Bengston, Elizabeth, Redd, Robert, Barnes, Jeffrey A., Takvorian, Tak, Sokol, Lubomir, Lansigan, Frederick, Armand, Philippe, Shah, Bijal, Jacobsen, Eric, Martignetti, Rosalba, Turba, Elyce, Metzler, Sara, Patterson, Victoria, LaCasce, Ann S., Bello, Celeste M.

“…•Brentuximab vedotin plus AD without radiation is an effective therapy for nonbulky limited-stage HL, with a favorable toxicity profile.•Risk of neutropenia,…”
Get full text

Nurses in clinical trials: perceptions of impact on the research enterprise by Jones, Carolynn T, Griffith, Catherine A, Fisher, Cheryl A, Grinke, Kathleen A, Keller, Rosemary, Lee, Hyacinth, Purdom, Michelle, Turba, Elyce

“…Background Clinical Research Nurses practice across a wide spectrum of roles and settings within the global research enterprise. Clinical Research Nurses…”
Get full text

Sequential Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide Is a Safe and Effective Regimen for the Treatment of Previously Treated and Untreated CLL/SLL: The Hilo Trial by Pinilla-Ibarz, Javier, Chavez, Julio C, Turba, Elyce, Nodzon, Lisa, rock-Klotz, Jennifer, Dalia, Samir, Komrokji, Rami S., Locke, Frederick L., Kharfan-Dabaja, Mohamed A, Bello, Celeste M.

“…Background: With the introduction of new targeted drugs for the treatment of CLL, a new therapeutic paradigm is emerging where chemo-immunotherapy is being…”
Get full text

Sézary Syndrome: Clinicopathological and Immunophenotypical Characteristics and Outcomes by Roe, Christa, Rock-Klotz, Jennifer, Turba, Elyce, Salamanca, Christopher Rodriguez, Bennett, Janice, Farquharson, Farrah, Bastien, Sem, Williams, Barbara, Levy, Rebecca, Li, Yibo, Montejo, Michael, Ayala, Ernesto, Horna, Pedro, Glass, Lewis F, Komrokji, Rami S., Sokol, Lubomir

“…Background Sézary syndrome (SS) is a rare malignant T-cell lymphoproliferative disorder derived from mature CD4+ T-helper/inducer cells. Patients (pts) with SS…”
Get full text

Durable Complete Response to AMG 655 (Conatumumab) and Vorinostat in a Patient With Relapsed Classical Hodgkin Lymphoma: Extraordinary Response from a Phase 1b Clinical Protocol by Skelton, William Paul, Turba, Elyce, Sokol, Lubomir

Get full text

Evaluating benign breast disease by Ellerhorst-Ryan, J M, Turba, E P, Stahl, D L

“…Benign breast diseases are present in some form in nearly all women. A basic understanding of breast anatomy and physiology, underlying pathology and methods…”
Get more information